secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2024-01-26T23:59:59+00:00
Accession:  0001104659-24-006963
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mallinckrodt extends CEO Siggi Olafsson's tenure 30 days through Feb 28 amid contract talks
--------------------------------------------------------------------------------

- CEO Olafsson had given notice of resignation effective Jan 29, 2024; agreed to stay through Feb 28, 2024.
- Extension includes $123,750 cash payment (target bonus for period) plus severance upon termination.
- Company is negotiating new employment agreement; no assurance Olafsson will remain beyond Feb 28.
- Reimbursement of legal/tax advisory fees for negotiations, subject to release if no new agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000110465924006963/0001104659-24-006963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000110465924006963/tm244193d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-006963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer